Ribonucleotide reductase as a therapeutic target for drug repurposing as anthelmintics

被引:2
|
作者
Panesso, Marcelo Pasa [1 ,2 ,3 ]
Cancela, Martin
Cora, Renato Kulakowski [1 ,2 ,3 ]
Paes, Jessica Andrade [1 ,2 ,3 ]
Paludo, Gabriela Prado [1 ,2 ,3 ]
Ferreira, Henrique Bunselmeyer [1 ,2 ,4 ]
机构
[1] Univ Fed Rio Grande do Sul UFRGS, Ctr Biotecnol, Lab Genom Estrutural & Func, Porto Alegre, Brazil
[2] Ctr Biotecnol, Lab Biol Mol Cestodeos, UFRGS, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biol Mol & Biotecnol, Porto Alegre, Brazil
关键词
Nucleotide synthesis; Echinococcus granulosus; Helminthiasis; Druggability; Drug repurposing; IN-VITRO; ECHINOCOCCUS; HYDROXYUREA; METABOLISM;
D O I
10.1016/j.exppara.2023.108641
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Visceral cestodiases, like echinococcoses and cysticercoses, are zoonoses of worldwide distribution and are responsible for public health problems in many countries, especially in underdeveloped regions. Current treatments have low efficiency and there are few drugs currently in use for chemotherapy, making the development of new anthelmintics an urgent matter. The nucleotide salvage pathways are the only ones available for nucleotide synthesis in cestodes and other parasitic helminths, and, here, we used in silico approaches to assess the potential of the enzymes in these pathways as targets for drug repurposing as anthelminthics. First, a genomic survey allowed to identify a repertoire of 28 enzymes of the purine and pyrimidine salvage pathways from the cestode Echinococcus granulosus sensu stricto. Regarding purines, the parasite relies on salvaging free bases rather than salvaging nucleosides. Pyrimidines, on the other hand, can be salvaged from both bases and nucleosides. Druggability of the parasite enzymes was assessed, as well as the availability of commercial inhibitors for them. Druggable enzymes were then ranked according to their potential for drug repurposing and the 17 most promising enzymes were selected for evolutionary analyses. The constructed phylogenetic trees allowed to assess the degree of conservation among ortholog enzymes from parasitic helminths and their mammalian hosts. Positive selection is absent in all assessed flatworm enzymes. A potential target enzyme for drug repurposing, ribonucleotide reductase (RNR), was selected for further assessment. RNR 3D-modelling showed structural similarities between the E. granulosus and the human orthologs suggesting that inhibitors of the human RNR should be effective against the E. granulosus enzyme. In line with that, E. granulosus protoscolices treated in vitro with the inhibitor hydroxyurea had their viability and DNA synthesis reduced. These results are consistent with nucleotide synthesis inhibition and confirm the potential of a nucleotide salvage inhibitors for repurposing as an anthelmintic.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Ribonucleotide reductase as a therapeutic target for glioma treatment
    Dos Santos, GG
    Edwards, A
    Kim, D
    Fillmor, H
    Elford, HL
    Broaddus, WC
    NEURO-ONCOLOGY, 2004, 6 (04) : 359 - 360
  • [2] Ribonucleotide reductase, a novel drug target for gonorrhea
    Narasimhan, Jana
    Letinski, Suzanne
    Jung, Stephen P.
    Gerasyuto, Aleksey
    Wang, Jiashi
    Arnold, Michael
    Chen, Guangming
    Hedrick, Jean
    Dumble, Melissa
    Ravichandran, Kanchana
    Levitz, Talya
    Cui, Chang
    Drennan, Catherine L.
    Stubbe, JoAnne
    Karp, Gary
    Branstrom, Arthur
    ELIFE, 2022, 11
  • [3] Anthelmintics for drug repurposing: Opportunities and challenges
    Alavi, Seyed Ebrahim
    Shahmabadi, Hasan Ebrahimi
    SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (05) : 434 - 445
  • [4] Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug
    Zhang, Xiaonan
    Selvaraju, Karthik
    Saei, Amir Ata
    D'Arcy, Padraig
    Zubarev, Roman A.
    Arner, Elias S. J.
    Linder, Stig
    BIOCHIMIE, 2019, 162 : 46 - 54
  • [5] Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
    L Dai
    Z Lin
    J Qiao
    Y Chen
    E K Flemington
    Z Qin
    Oncogene, 2017, 36 : 5068 - 5074
  • [6] RIBONUCLEOTIDE REDUCTASE AS A CHEMOTHERAPEUTIC TARGET
    CORY, JG
    ADVANCES IN ENZYME REGULATION, 1988, 27 : 437 - 455
  • [7] Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
    Dai, L.
    Lin, Z.
    Qiao, J.
    Chen, Y.
    Flemington, E. K.
    Qin, Z.
    ONCOGENE, 2017, 36 (35) : 5068 - 5074
  • [8] Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study
    Mohanty, Partha Sarathi
    Bansal, Avi Kumar
    Naaz, Farah
    Gupta, Umesh Datta
    Dwivedi, Vivek Dhar
    Yadava, Umesh
    INFECTION GENETICS AND EVOLUTION, 2018, 60 : 58 - 65
  • [9] DRUG-ACTION ON RIBONUCLEOTIDE REDUCTASE
    CORY, JG
    CARTER, GL
    ADVANCES IN ENZYME REGULATION, 1985, 24 : 385 - 401
  • [10] RIBONUCLEOTIDE REDUCTASE AS A MAIN TARGET OF METHYLNITROSOUREA INVIVO
    FILATOV, DE
    KUDRYAVTSEV, ME
    BAIDER, LM
    SHARYGIN, VL
    GRYAKALOV, KV
    PULATOVA, MK
    KORMAN, DB
    IZVESTIYA AKADEMII NAUK SSSR SERIYA BIOLOGICHESKAYA, 1991, (04): : 528 - 539